Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

Trial Details

NCT ID

NCT06980532

Phase

PHASE1 / PHASE2

Sponsor

Liu Huang

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Glumetinib Combined with Fruquintinib

Locations (sample)

• Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

• The patients fully understood this study, voluntarily participated and signed the Informed Consent Form (ICF);
• Age ≥18 years old;
• Patients with unresectable metastatic colorectal cancer with microsatellite stable (MSS) confirmed by pathology or histology;
• Have MET amplification (FISH MET GCN≥4 or MET/CEP7≥1.8; Or NGS, ≥20% of tumor cells, ≥200X sequencing depth, GCN≥4) or overexpression (IHC, 3+(≥50%…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.